Mutch D - Search Results

1

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.

Mutch D, Voulgari A, Chen XM, Bradley WH, Oaknin A, Perez Fidalgo JA, Montosa FG, Herraez AC, Holloway RW, Powell MA, Nowicka M, Schaefer G, Merchant M, Yan Y. Mutch D, et al. Cancer. 2024 Jun 1;130(11):1940-1951. doi: 10.1002/cncr.35222. Epub 2024 Jan 30. Cancer. 2024. PMID: 38288862 Clinical Trial.

2

Analysis of exposure times and dose escalation of paclitaxel in ovarian cancer cell lines.

Adler LM, Herzog TJ, Williams S, Rader JS, Mutch DG. Adler LM, et al. Among authors: mutch dg. Cancer. 1994 Oct 1;74(7):1891-8. doi: 10.1002/1097-0142(19941001)74:7<1891::aid-cncr2820740711>3.0.co;2-k. Cancer. 1994. PMID: 7915965

3

Cyclosporin enhancement of cisplatin chemotherapy in patients with refractory gynecologic cancer. A Gynecologic Oncology Group Study.

Manetta A, Boyle J, Berman ML, DiSaia PJ, Lentz S, Liao SY, Mutch D, Slater L. Manetta A, et al. Among authors: mutch d. Cancer. 1994 Jan 1;73(1):196-9. doi: 10.1002/1097-0142(19940101)73:1<196::aid-cncr2820730134>3.0.co;2-f. Cancer. 1994. PMID: 8275425 Clinical Trial.

4

Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability.

Swisher EM, Peiffer-Schneider S, Mutch DG, Herzog TJ, Rader JS, Elbendary A, Goodfellow PJ. Swisher EM, et al. Among authors: mutch dg. Cancer. 1999 Jan 1;85(1):119-26. doi: 10.1002/(sici)1097-0142(19990101)85:1<119::aid-cncr17>3.0.co;2-5. Cancer. 1999. PMID: 9921983

5

Epithelial ovarian tumors of low malignant potential: the role of microinvasion.

Buttin BM, Herzog TJ, Powell MA, Rader JS, Mutch DG. Buttin BM, et al. Obstet Gynecol. 2002 Jan;99(1):11-7. doi: 10.1016/s0029-7844(01)01675-1. Obstet Gynecol. 2002. PMID: 11777503

6

Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker.

Powell MA, Mutch DG, Rader JS, Herzog TJ, Huang TH, Goodfellow PJ. Powell MA, et al. Cancer. 2002 Jun 1;94(11):2941-52. doi: 10.1002/cncr.10559. Cancer. 2002. PMID: 12115383 Free article.

7

MSI in endometrial carcinoma: absence of MLH1 promoter methylation is associated with increased familial risk for cancers.

Whelan AJ, Babb S, Mutch DG, Rader J, Herzog TJ, Todd C, Ivanovich JL, Goodfellow PJ. Whelan AJ, et al. Int J Cancer. 2002 Jun 10;99(5):697-704. doi: 10.1002/ijc.10429. Int J Cancer. 2002. PMID: 12115503 Free article.

8

Increased risk for hereditary nonpolyposis colorectal cancer-associated synchronous and metachronous malignancies in patients with microsatellite instability-positive endometrial carcinoma lacking MLH1 promoter methylation.

Buttin BM, Powell MA, Mutch DG, Rader JS, Herzog TJ, Gibb RK, Huettner P, Edmonston TB, Goodfellow PJ. Buttin BM, et al. Clin Cancer Res. 2004 Jan 15;10(2):481-90. doi: 10.1158/1078-0432.ccr-1110-03. Clin Cancer Res. 2004. PMID: 14760069

9

Synchronous ovarian metastases at the time of laparotomy for colon cancer.

Wright JD, Powell MA, Mutch DG, Rader JS, Gibb RK, Huettner PC, Herzog TJ. Wright JD, et al. Among authors: mutch dg. Gynecol Oncol. 2004 Mar;92(3):851-5. doi: 10.1016/j.ygyno.2003.12.017. Gynecol Oncol. 2004. PMID: 14984952

10

Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history.

Buttin BM, Powell MA, Mutch DG, Babb SA, Huettner PC, Edmonston TB, Herzog TJ, Rader JS, Gibb RK, Whelan AJ, Goodfellow PJ. Buttin BM, et al. Am J Hum Genet. 2004 Jun;74(6):1262-9. doi: 10.1086/421332. Epub 2004 Apr 19. Am J Hum Genet. 2004. PMID: 15098177 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

657 results

Search Page